Onchilles Pharma is a biotechnology company developing first-in-class biologics therapies for the treatment of cancer.
Onchilles Pharma has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in November 2025.
Onchilles Pharma's investors include Kennedy Lewis Investment Management, LYZZ Capital, Lincoln Park Capital Fund, InVivium Capital, Polsky Center at the University of Chicago.
Onchilles Pharma is headquartered in San Diego, United States.
Onchilles Pharma is a biotechnology company developing first-in-class biologics therapies for the treatment of cancer.
Onchilles Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Onchilles Pharma — Funding & Investors." VCBacked, November 7, 2025, https://www.vcbacked.co/company/onchilles-pharma. Accessed September 16, 2026.
VCBacked. (2025). Onchilles Pharma — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/onchilles-pharma
{{cite web |title=Onchilles Pharma — Funding & Investors |url=https://www.vcbacked.co/company/onchilles-pharma |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated